Illumina (ILMN) – Reuters
-
EU merger powers may be curbed after court adviser backs Illumina fight
-
Exclusive-Icahn drops Illumina board challenge threat, sources say
-
Illumina forecasts flat 2024 sales as sluggish demand drags on
-
Activist Icahn prepares a second board challenge at Illumina -letter
-
Illumina accuses EU of over-extending its powers in assessing Grail deal
-
Illumina to divest Grail within a year if it does not win challenge in EU court
-
Illumina ordered by EU antitrust regulators to sell Grail
-
Illumina to divest cancer test maker Grail if it loses US or EU court appeal
-
Illumina cuts annual profit forecast as biotech funding woes linger
-
Illumina hit with record $476 million EU antitrust fine over Grail deal
-
Illumina starts job cuts, plans office exit to rein in costs
-
Illumina expands board after fight with Icahn
-
Illumina CEO survived Icahn's challenge by more than 2-to-1 margin
-
Icahn scores partial Illumina win amid pressure to defend investment acumen
-
Exclusive-Icahn poised to win at least one seat on Illumina's board -sources
-
US FTC orders Illumina to divest cancer detection test maker Grail
-
Carl Icahn wants to bring back Illumina's ex-CEO -WSJ
-
Icahn urges Illumina to unwind Grail deal, pushes ahead on proxy fight
-
Icahn launches proxy fight at Illumina, seeks board seats
-
Illumina fights EU order to divest Grail
-
Exclusive-Illumina to face EU fine of 10% of turnover over Grail deal -sources
-
Illumina challenges EU order to keep Grail separate
-
Exclusive: EU antitrust regulators likely to block Illumina, Grail deal - sources
-
Exclusive: Illumina, Grail deal faces EU antitrust veto - sources
-
EU says Illumina risks hefty fine for jumping gun on Grail deal
-
Illumina loses challenge against EU antitrust probe into Grail deal
-
Exclusive-Illumina remedies on Grail bid unconvincing to EU antitrust regulators, sources say
-
Illumina moves to allay EU antitrust concerns over $8 billion Grail deal
-
Illumina expects EU order to keep Grail a separate company
-
FTC urges judge to unwind $7.1 billion Illumina-Grail merger
-
Illumina in EU antitrust sights over premature $8 billion Grail deal
-
Illumina deal for Grail could hurt innovation, EU warns
-
Exclusive-Illumina, Grail deal faces full-scale EU antitrust probe -sources
-
Illumina to buy Jeff Bezos-backed cancer testing firm Grail in $8 billion deal
-
Qiagen CEO quits amid genetic sequencing U-turn, shares tumble
-
Wall St. notches all-time highs on lingering rate-cut optimism
-
S&P ends flat as healthcare advance offset by lower oil
-
Wall Street stocks slide, dollar hits eight-month high
Back to ILMN Stock Lookup
